Patents Assigned to AB Science
  • Compounds with anti-tumoral activity
    Patent number: 10570122
    Abstract: The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: February 25, 2020
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • Oxazole derivatives that inhibit Syk
    Patent number: 10392373
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 27, 2019
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Claire Schalon, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • METHOD FOR DETERMINING THE PROGNOSIS OF PANCREATIC CANCER
    Publication number: 20160244845
    Abstract: An in vitro method for determining the prognosis of pancreatic cancer in a patient includes the following steps: a) measuring the expression level of at least one gene chosen from the group consisting of: ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ and RPS23 or homologous genes, in a blood sample of the patient, b) predicting the outcome of the pancreatic cancer in the patient. a kit specifically designed to carry out such a method is also described.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Applicants: AB Science, ACOBIOM
    Inventors: David PIQUEMAL, Alain MOUSSY, Jean-Pierre KINET
  • 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
    Patent number: 8993573
    Abstract: Novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 31, 2015
    Assignee: AB Science
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Giethlen, Alain Moussy
  • Thiazole and oxazole kinase inhibitors
    Patent number: 8962665
    Abstract: The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: February 24, 2015
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Jason Martin, Emmanuel Chevenier, Didier Pez, Franck Sandrinelli, Willy Picoul
  • Aminothiazole compounds as kinase inhibitors and methods of using the same
    Patent number: 8940894
    Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula I: which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: January 27, 2015
    Assignee: AB Science
    Inventors: Alain Moussy, Philippe Reginault, Francois Bellamy, Anne Lermet
  • Treatment of multiple sclerosis with masitinib
    Patent number: 8906357
    Abstract: The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human multiple sclerosis.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: December 9, 2014
    Assignee: AB Science
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
    Patent number: 8835435
    Abstract: Novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: September 16, 2014
    Assignee: AB Science
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Giethlen, Alain Moussy
  • Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
    Patent number: 8658659
    Abstract: The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Flt-3 inhibitors.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: February 25, 2014
    Assignees: AB Science, Centre National de la Recherche Scientifique (CNRS), Institut Curie
    Inventors: David Grierson, Abdellah Benjahad, Alain Moussy, Martine Croisy
  • Aminothiazole compounds as kinase inhibitors and methods of using the same
    Patent number: 8492545
    Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula I: which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: July 23, 2013
    Assignee: AB Science
    Inventors: Alain Moussy, Philippe Reginault, Francois Bellamy, Anne Lermet
  • 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
    Patent number: 8450302
    Abstract: The present invention relates to the use of masitinib or a pharmaceutically acceptable salt thereof, and in particular of masitinib mesylate, for the preparation of a medicament for the treatment of GIST, to the use of this therapy for the treatment of GIST, and a method of treating mammals, including humans, suffering from GIST by administering to said mammal in need of such treatment an effective dose of masitinib, and in particular masitinib mesylate.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: May 28, 2013
    Assignee: AB Science
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Giethlen, Alain Moussy, Jean-Pierre Kinet
  • Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
    Patent number: 8227470
    Abstract: The present invention relates to a method for treating solid cancers including non-small 5 cell lung cancer, pancreatic, bladder, breast and ovarian cancer as well as advanced biliary tract cancers comprising administering at least one antineoplasticagent such as a nucleotide analog, for example gemcitabine, or an antimitotic such as docetaxel, in combination with a tyrosine kinase inhibitor selected from 2-aminoarylthiazoles and 2-aminoaryloxazoles.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: July 24, 2012
    Assignee: AB Science
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
    Patent number: 8153792
    Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula (1) which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: April 10, 2012
    Assignee: AB Science
    Inventors: Alain Moussy, Philippe Reginault, François Bellamy, Anne Lermet
  • 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
    Patent number: 8110591
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: February 7, 2012
    Assignees: AB Science, Centre National de la Recherche Scientifique (CNRS), Institut Curie
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • Process for the synthesis of 2-aminoxazole compounds
    Patent number: 8080669
    Abstract: The present invention relates to a process for synthesizing in good yield substituted 2-aminoaryloxazole compounds of formula I which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit, bcr-abl, Flt-3 and mutant forms thereof.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: December 20, 2011
    Assignee: AB Science
    Inventor: Abdellah Benjahad
  • Use of tyrosine kinase inhibitors for treating inflammatory diseases
    Patent number: 7741335
    Abstract: The present invention relates to a method for treating inflammatory diseases such as rheumatoid arthritis (RA), comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 22, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Jean Pierre Kinet
  • Potent, selective and non toxic c-kit inhibitors
    Patent number: 7727731
    Abstract: The present invention relates to a screening method allowing the identification and selection of compounds targeting the transphosphorylase (also called phosphotransferase) domain of c-kit, more particularly compounds selected to be potent inhibitors of constitutively activated c-kit, while being unable to inhibit other activation pathways as for example the pathways leading to death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 1, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Patrice Dubreuil, Olivier Hermine
  • 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
    Patent number: 7718676
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: May 18, 2010
    Assignees: AB Science, Centre National de la Recherche Scientifique (CNRS), Institut Curie
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • Use of tyrosine kinase inhibitors for treating allergic diseases
    Patent number: 7700610
    Abstract: The present invention relates to a method for treating allergic diseases such as asthma, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: April 20, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
    Patent number: 7678805
    Abstract: The present invention relates to a method for treating inflammatory bowel diseases (IBD), such as crohn's disease, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: March 16, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Jean-Pierre Kinet